[HTML][HTML] Treatment patterns, direct cost of biologics, and direct medical costs for rheumatoid arthritis patients: a real-world analysis of nationwide Japanese claims data
N Sugiyama, Y Kawahito, T Fujii, T Atsumi, T Murata… - Clinical …, 2016 - Elsevier
Purpose The aims of this article were to characterize the patterns of treating rheumatoid
arthritis with biologics and to evaluate costs using claims data from the Japan Medical Data …
arthritis with biologics and to evaluate costs using claims data from the Japan Medical Data …
Estimating effectiveness and cost of biologics for rheumatoid arthritis: application of a validated algorithm to commercial insurance claims
JR Curtis, VF Schabert, DJ Harrison, J Yeaw… - Clinical …, 2014 - Elsevier
Purpose The aim of this analysis was to implement a claims-based algorithm to estimate
biologic cost per effectively treated patient for biologics approved for moderate to severe …
biologic cost per effectively treated patient for biologics approved for moderate to severe …
Comparison of healthcare costs between rheumatoid arthritis patients treated with infused biologics after switching from another biologic
SS Johnston, D McMorrow, AM Farr, P Juneau… - Drugs-Real World …, 2015 - Springer
Introduction While there is a substantial body of literature on the comparative healthcare
costs of biologics used to treat rheumatoid arthritis (RA), nearly all of these investigations …
costs of biologics used to treat rheumatoid arthritis (RA), nearly all of these investigations …
Wide difference in biologics usage and expenditure for the treatment of patients with rheumatoid arthritis in each prefecture in Japan analyzed using “National …
Y Kamata, S Minota - Rheumatology International, 2018 - Springer
To analyze the biologics usage and expenditure for the treatment of patients with
rheumatoid arthritis (RA) in each prefecture throughout Japan using the national open …
rheumatoid arthritis (RA) in each prefecture throughout Japan using the national open …
Economic burden and treatment patterns of cycling between conventional synthetic disease-modifying antirheumatic drugs among biologic-treated patients with …
KA Betts, J Griffith, A Ganguli, N Li, K Douglas… - Clinical …, 2016 - Elsevier
Purpose To assess the economic outcomes and treatment patterns among patients with
rheumatoid arthritis (RA) who used 1, 2, or 3 or more conventional synthetic disease …
rheumatoid arthritis (RA) who used 1, 2, or 3 or more conventional synthetic disease …
Analysis and breakdown of overall 1-year costs relative to inpatient and outpatient care among rheumatoid arthritis patients treated with biotherapies using health …
M Beck, M Velten, MC Rybarczyk-Vigouret… - Drugs-Real World …, 2015 - Springer
Background The economic burden linked to rheumatoid arthritis (RA) has greatly increased
since the inclusion of biotherapies in the therapeutic arsenal. Objectives This study aimed …
since the inclusion of biotherapies in the therapeutic arsenal. Objectives This study aimed …
Comparing biologic cost per treated patient across indications among adult US managed care patients: a retrospective cohort study
T Gu, N Shah, G Deshpande, DH Tang… - Drugs-real world …, 2016 - Springer
Background The relative cost of biologics in the treatment of autoimmune disorders,
including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a …
including rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis, is a …
Effectiveness and costs among rheumatoid arthritis patients treated with targeted immunomodulators using real-world US data
M Gharaibeh, M Bonafede, D McMorrow… - Journal of Managed …, 2020 - jmcp.org
This article has been corrected. Please see J Manag Care Spec Pharm, 2020; 26 (10): 1256
BACKGROUND: Targeted immunomodulators (TIMs) are used for the treatment of moderate …
BACKGROUND: Targeted immunomodulators (TIMs) are used for the treatment of moderate …
Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study
TD Gilbert, D Smith, DA Ollendorf - BMC Musculoskeletal Disorders, 2004 - Springer
Background Variability in dosing and costs of biologics among patients with rheumatoid
arthritis (RA) is of interest to healthcare descision-makers. We examined dosing and costs …
arthritis (RA) is of interest to healthcare descision-makers. We examined dosing and costs …
Cost-effectiveness analysis of treatment sequence initiating with etanercept compared with leflunomide in rheumatoid arthritis: impact of reduced etanercept cost with …
SK Park, SH Park, MY Lee, JH Park, JH Jeong… - Clinical Therapeutics, 2016 - Elsevier
Abstract Purpose In south Korea, the price of biologics has been decreasing owing to patent
expiration and the availability of biosimilars. This study evaluated the cost-effectiveness of a …
expiration and the availability of biosimilars. This study evaluated the cost-effectiveness of a …
相关搜索
- direct medical costs
- rheumatoid arthritis cost of biologics
- arthritis patients treatment patterns
- rheumatoid arthritis insurance claims
- rheumatoid arthritis patterns of cycling
- rheumatoid arthritis treatment sequence
- rheumatoid arthritis validated algorithm
- rheumatoid arthritis antirheumatic drugs
- rheumatoid arthritis economic impact
- cost of biologics insurance claims
- cost of biologics validated algorithm
- arthritis patients effectiveness and costs
- arthritis patients targeted immunomodulators
- arthritis patients outpatient care
- biologic cost treated patient
- cost effectiveness treatment sequence